PGEN PRECIGEN, INC.

Nasdaq precigen.com


$ 3.35 $ 0.10 (3.08 %)    

Wednesday, 15-Oct-2025 11:26:23 EDT
QQQ $ 605.60 $ 1.74 (0.29 %)
DIA $ 465.58 $ 0.94 (0.2 %)
SPY $ 668.05 $ 1.29 (0.19 %)
TLT $ 91.20 $ 0.24 (0.26 %)
GLD $ 386.72 $ 0.79 (0.2 %)
$ 3.2
$ 3.22
$ 3.35 x 635
$ 3.36 x 1,838
$ 3.22 - $ 3.38
$ 0.65 - $ 5.23
4,200,651
na
953.51M
$ 1.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-19-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-19-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 precigen-reports-responses-to-papzimeos-in-adults-with-recurrent-respiratory-papillomatosis-reinforcing-fda-approval

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

 precigen-entered-into-a-credit-facility-agreement-with-pharmakon-advisors-for-up-125m-in-non-dilutive-funding

The credit facility provides Precigen with up to $125 million committed across two tranches, subject to the terms and condition...

 jmp-securities-maintains-market-outperform-on-precigen-raises-price-target-to-8

JMP Securities analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target...

 hc-wainwright--co-reiterates-buy-on-precigen-maintains-85-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $8.5 price...

 why-is-precigen-stock-surging-on-friday

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable...

 jp-morgan-upgrades-precigen-to-neutral

JP Morgan analyst Brian Cheng upgrades Precigen (NASDAQ:PGEN) from Underweight to Neutral.

 hc-wainwright--co-maintains-buy-on-precigen-raises-price-target-to-85

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION